Abstract:The discovery of insulin and the introduction of peripherally injected insulin therapy for type 1 diabetes mellitus (T1DM) transformed a universally fatal disease into one that was compatible with life. Current diabetes management regimens attempt to mimic pancreatic insulin secretion with the ultimate goal of normalization of life span and restoration of quality of life for patients with T1DM. This strategy necessitates balancing the insulin requirements of systemically supplied muscle and adipose tissue, which are achieved by subcutaneously administered insulin, and the requirements of hepatocytes and pancreatic α cells, which in non-diabetic subjects are exposed to higher insulin concentrations in the portal circulation. Thus, while satisfying hepatic insulin requirements may have beneficial effects, such as on lipid metabolism, peripheral administration of sufficient doses of insulin to achieve this homeostasis increases the risk of hypoglycemia. To resolve these two apparently conflicting insulin dosing requirements one of the strategies being pursued is the development of techniques that enable administration of insulin into the portal circulation (1, 2). An alternative strategy is to design adjunctive therapy to insulin that could compensate for the increased insulin requirement of hepatocytes and pancreatic α cells. In the March 1, 2010 issue of the Proceedings of the National Academy of Sciences, Roger Unger’s group report that addition of leptin to insulin therapy reverses the catabolic state of T1DM by maintaining glycemic control and suppressing glucagon secretion from pancreatic α cells (3). Leptin is a hormone belonging to the long-chain helical cytokine family which is secreted from adipocytes and plays a key role in the central regulation of appetite, energy balance, nutritional status and immune response. In the current study nonobese diabetic (NOD) mice with uncontrolled type 1 diabetes were treated with leptin, insulin, or combination therapy. The addition of leptin to the insulin regimen resulted in decreased glucose concentration variability which is attributed to suppression of glucagon secretion by pancreatic α cells (3, 4). Treatment with leptin achieved metabolic homeostasis with anabolic effects on protein and carbohydrate metabolism. Leptin therapy also improved fatty acid oxidation, decreased cholesterologenic transcription factors, and lowered triglyceride levels with ensuing improvements in fatty acid and cholesterol metabolism. Overall, animals treated with insulin and leptin combination therapy demonstrated improvements in glucose variability, normalized serum glucose, and improved serum triglycerides levels. This study raises the possibility that leptin used as adjuvant therapy with insulin could offer significant advantages over conventional regimes based on insulin alone. Whereas the current study sheds light on important aspects of metabolic homeostasis in T1DM and raises the intriguing possibility of using leptin to dampen glucose excursions in T1DM, there are significant caveats and hurdles that will have to be clarified or circumvented before this strategy can be applied to the human. The first issue is that of dosage. The leptin dose used in this study was much higher than have been used thus far in the limited number of studies in the human and key points related to safety, dosage, and side-effects are yet to be determined (5–7). Leptin exerts effects on pubertal development (8) and since the majority of cases of T1DM are diagnosed during childhood, the potential effect(s) of leptin therapy on pubertal development is of particular significance. The second issue is that of leptin resistance. It is well established that diet-induced obesity is characterized by leptin resistance and hyperleptinemia (9). Hence the salutary effects observed in the study following the short term administration of leptin could be negated in the long-term by the development of leptin resistance. In this regard, it is noteworthy that earlier studies using somatostatin analogues in patients with T1DM as a means of regulating blood sugar levels via suppression of glucagon secretion yielded only transient effects as a result of the development of desensitization (10). The third caveat is that leptin is known to exert immunomodulatory effects (11). Matarese et al. provided evidence that in the NOD mouse leptin might be a critical endocrine contributor to the activation of diabetogenic T cells (12). In their study, Matarese et al. demonstrated that weekly injections between 1 and 4

Improving type 1 diabetes control with leptin – Is this a game‐changer?

Principles of Hair Cycle Control

Epidermal retinol dehydrogenases cyclically regulate stem cell markers and clock genes and influence hair composition

Diurnal Preference Predicts Phase Differences in Expression of Human Peripheral Circadian Clock Genes

Cultivation of Human Hair Follicle Cells

Fgf and Wnt signaling interaction in the mesenchymal niche regulates the murine hair cycle clock

A simple method using ex vivo culture of hair follicle tissue to investigate intrinsic circadian characteristics in humans

O01 Mapping the cellular and molecular dynamics of mouse and human hair follicles reveals mechanisms of hair growth

Differential Regulation of Circadian Clock Genes by UV-B Radiation and 1,25-Dihydroxyvitamin D: A Pilot Study during Different Stages of Skin Photocarcinogenesis

CRY Drives Cyclic CK2-Mediated BMAL1 Phosphorylation to Control the Mammalian Circadian Clock

BMAL1 positively correlates with genes regulating steroidogenesis in human luteinized granulosa cells

Time-course RNA-seq analysis reveals stage-specific and melatonin-triggered gene expression patterns during the hair follicle growth cycle in Capra hircus

An Intrinsic Oscillation of Gene Networks Inside Hair Follicle Stem Cells: An Additional Layer That Can Modulate Hair Stem Cell Activities

Physical Interaction between Cyclin-Dependent Kinase 5 (CDK5) and Clock Factors Affects the Circadian Rhythmicity in Peripheral Oscillators

Molecular Mechanisms of Hair Growth and Regeneration: Current Understanding and Novel Paradigms

Cell-specific regulation of the circadian clock by BMAL1 in the paraventricular nucleus: Implications for regulation of systemic biological rhythms

High-Throughput Chemical Screen Identifies A Novel Potent Modulator Of Cellular Circadian Rhythms And Reveals Cki Alpha As A Clock Regulatory Kinase

Mitochondrial mutations associated with aminoglycoside ototoxicity and hearing loss susceptibility identified by meta-analysis

A multi-scale model for hair follicles reveals heterogeneous domains driving rapid spatiotemporal hair growth patterning

Molecular Mechanisms that Regulate the Coupled Period of the Mammalian Circadian Clock

Chronobiological Analysis of Circadian Patterns in Transcription of Seven Key Clock Genes in Six Peripheral Tissues in Mice